Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.
Kerr
D J
DJ
University of Birmingham CRC Institute for Cancer Studies, Queen Elizabeth Hospital, UK.
Rustin
G J
GJ
Kaye
S B
SB
Selby
P
P
Bleehen
N M
NM
Harper
P
P
Brampton
M H
MH
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D007783:Lactones / Q000627:therapeutic use; D018942:Macrolides; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D007783:Lactones; D018942:Macrolides; C041443:rhizoxin